188 related articles for article (PubMed ID: 38865670)
1. Poly(ADP-Ribose) Polymerase Inhibitor Development: Promising Strategies to Move Beyond Approved Indications.
Torrado C; Plummer R; Yap TA
JCO Precis Oncol; 2024 Jun; 8():e2400204. PubMed ID: 38865670
[TBL] [Abstract][Full Text] [Related]
2. PARP inhibitor combination therapy.
Dréan A; Lord CJ; Ashworth A
Crit Rev Oncol Hematol; 2016 Dec; 108():73-85. PubMed ID: 27931843
[TBL] [Abstract][Full Text] [Related]
3. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
4. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
5. An Update on Poly(ADP-ribose) Polymerase I-A Brief Review.
Negi P; Lakshmanan K; Patel PK; Rajagopal K; Byran G
Mini Rev Med Chem; 2023; 23(18):1762-1771. PubMed ID: 36824002
[TBL] [Abstract][Full Text] [Related]
6. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
Papa A; Caruso D; Strudel M; Tomao S; Tomao F
J Transl Med; 2016 Sep; 14():267. PubMed ID: 27634150
[TBL] [Abstract][Full Text] [Related]
7. Delving into PARP inhibition from bench to bedside and back.
Grignani G; Merlini A; Sangiolo D; D'Ambrosio L; Pignochino Y
Pharmacol Ther; 2020 Feb; 206():107446. PubMed ID: 31756364
[TBL] [Abstract][Full Text] [Related]
8. Small-Molecule Inhibitors of PARPs: From Tools for Investigating ADP-Ribosylation to Therapeutics.
Kirby IT; Cohen MS
Curr Top Microbiol Immunol; 2019; 420():211-231. PubMed ID: 30242511
[TBL] [Abstract][Full Text] [Related]
9. PARP and PARG inhibitors in cancer treatment.
Slade D
Genes Dev; 2020 Mar; 34(5-6):360-394. PubMed ID: 32029455
[TBL] [Abstract][Full Text] [Related]
10. Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer.
Markman M
Womens Health (Lond); 2018; 14():1745505717750694. PubMed ID: 29313444
[TBL] [Abstract][Full Text] [Related]
11. Poly(ADP-ribose) polymerase inhibition: past, present and future.
Curtin NJ; Szabo C
Nat Rev Drug Discov; 2020 Oct; 19(10):711-736. PubMed ID: 32884152
[TBL] [Abstract][Full Text] [Related]
12. Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations.
Ngoi NYL; Westin SN; Yap TA
Curr Opin Oncol; 2022 Sep; 34(5):559-569. PubMed ID: 35787597
[TBL] [Abstract][Full Text] [Related]
13. A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
Li Y; Liu CF; Rao GW
Curr Med Chem; 2021; 28(8):1565-1584. PubMed ID: 32164505
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors.
Chu YY; Yam C; Yamaguchi H; Hung MC
J Biomed Sci; 2022 Oct; 29(1):86. PubMed ID: 36284291
[TBL] [Abstract][Full Text] [Related]
15. Latest clinical evidence and further development of PARP inhibitors in ovarian cancer.
Mirza MR; Pignata S; Ledermann JA
Ann Oncol; 2018 Jun; 29(6):1366-1376. PubMed ID: 29750420
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities.
Rajawat J; Shukla N; Mishra DP
Med Res Rev; 2017 Nov; 37(6):1461-1491. PubMed ID: 28510338
[TBL] [Abstract][Full Text] [Related]
17. Platinated benzonaphthyridone is a stronger inhibitor of poly(ADP-ribose) polymerase-1 and a more potent anticancer agent than is the parent inhibitor.
Wang B; Qian H; Yiu SM; Sun J; Zhu G
Eur J Med Chem; 2014 Jan; 71():366-73. PubMed ID: 24361480
[TBL] [Abstract][Full Text] [Related]
18. Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer.
McCann KE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):7-16. PubMed ID: 29251678
[TBL] [Abstract][Full Text] [Related]
19. Development of poly ADP-ribose polymerase-1 inhibitor with anti-cervical carcinoma activity.
Zhang TM; Wang W
Cell Mol Biol (Noisy-le-grand); 2020 Oct; 66(7):31-34. PubMed ID: 33287919
[TBL] [Abstract][Full Text] [Related]
20. Structural Requirements of Some 2-(1-Propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide Derivatives as Poly (ADP-Ribose) Polymerase (PARP) for the Treatment of Cancer: QSAR Approach.
Sharma MC
Interdiscip Sci; 2016 Mar; 8(1):11-22. PubMed ID: 26205198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
